The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

BACKGROUND: In 6-month anti-dementia drug trials, a 4-point change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is held to be clinically important. We examined how this change compared with measures of clinical meaningfulness. METHODS: This is a secondary analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rockwood, Kenneth, Fay, Sherri, Gorman, Mary, Carver, Daniel, Graham, Janice E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034585/
https://www.ncbi.nlm.nih.gov/pubmed/17760991
http://dx.doi.org/10.1186/1471-2377-7-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034585/
https://www.ncbi.nlm.nih.gov/pubmed/17760991
http://dx.doi.org/10.1186/1471-2377-7-26

Ejemplares similares